Product Program year 2021 Source: CMS Open Payments

Thyquidity

Drug Hypothyroidism

NDC 66689-105-02

Open in the dashboard

General payments

$87,082

2,597 payments

Research payments

$0

0 payments

Through program year 2021, $87,082 in general payments and $0 in research payments were reported against Thyquidity (Hypothyroidism).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

1 row
Year Kind Amount Payments
2021 General $87,082 2,597

Breakdown

Who paid General payments · program year 2021
  1. VistaPharm, Inc. $87,082 2,597 payments
Top recipients General payments · program year 2021
  1. Yehuda Handelsman Endocrinology, Diabetes & Metabolism · Tarzana, CA $8,700 10% · 6 payments
  2. Daniel Einhorn Endocrinology, Diabetes & Metabolism · La Jolla, CA $4,250 5% · 5 payments
  3. Bradley Miller Pediatric Endocrinology · Minneapolis, MN $4,000 5% · 1 payment
  4. Thomas Blevins Endocrinology, Diabetes & Metabolism · Austin, TX $3,767 4% · 5 payments
  5. Anastasios Manessis Endocrinology, Diabetes & Metabolism · New York, NY $3,488 4% · 5 payments

The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2021.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2021
  1. Endocrinology, Diabetes & Metabolism Internal Medicine $42,665 51% · 263 practitioners
  2. Pediatric Endocrinology Pediatrics $16,104 19% · 38 practitioners
  3. Family Medicine $6,312 7% · 352 practitioners
  4. Internal Medicine $5,538 7% · 271 practitioners
  5. Nurse Practitioner, Family Nurse Practitioner $4,520 5% · 231 practitioners

The top 5 of 49 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2021
  1. California $19,952 23% · 91 recipients
  2. New York $15,661 18% · 229 recipients
  3. Texas $9,614 11% · 284 recipients
  4. Pennsylvania $5,133 6% · 70 recipients
  5. Florida $4,223 5% · 225 recipients

The top 5 of 45 states; each share is of general payments naming this product in 2021 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

179

Prescriptions dispensed, refills included

Drug cost

$36,174

Paid at the pharmacy, in all

Prescribers

13

With 11 or more claims of it

Medicare Part D drugs matched to Thyquidity, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Thyquidity Levothyroxine Sodium Same name 13 179 $36,174

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 13 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Sarah Yong General Practice FL 22 $3,101 None on record
Leila Chaychi Endocrinology CA 16 $3,354 None on record
Susan Thompson Internal Medicine ND 16 $2,272 None on record
Alyssa Sader Family Practice OR 16 $2,229 None on record
Leslie Bryant Family Practice AK 14 $2,466 None on record

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 13 in the dashboard with a free account
2,597 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2021

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record